DeepMed Research

The Case Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1826-01-01

Employees: 5K

Market Cap: -

Website: http://www.case.edu/cancer

Clinical Trials

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1

Terminated

Conditions: Recurrent Small Lymphocytic Lymphoma
Stage III Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia
Stage III Small Lymphocytic Lymphoma
Stage IV Small Lymphocytic Lymphoma

Interventions: Drug: Bendamustine Hydrochloride
Biological: Alemtuzumab

First Posted Date: 2009-07-28

Last Posted Date: 2013-08-22

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT00947388

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Radiation Therapy in Treating Patients With Recurrent Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Radiation: intraoperative radiation therapy
Radiation: intracavitary balloon brachytherapy

First Posted Date: 2009-07-23

Last Posted Date: 2020-08-18

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 13

Registration Number: NCT00945061

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
UHHS Chagrin Highlands Medical Center, Cleveland, Ohio, United States
🇺🇸
UHHS Westlake Medical Center, Cleveland, Ohio, United States

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: busulfan
Drug: cyclophosphamide
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2009-07-20

Last Posted Date: 2020-07-24

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 71

Registration Number: NCT00941720

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Laser Spectroscopy of Breast Tissue Through a Needle Device

Completed

Conditions: Breast Cancer

First Posted Date: 2009-06-11

Last Posted Date: 2013-08-22

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 17

Registration Number: NCT00918788

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Assessment of Candidate Protein Expression in Breast Cancer Specimens

Completed

Conditions: Breast Cancer

First Posted Date: 2009-06-11

Last Posted Date: 2022-08-01

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 460

Registration Number: NCT00918892

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer

Terminated

Conditions: Leukemia
Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Other: biologic sample preservation procedure
Other: immunologic technique
Other: laboratory biomarker analysis

First Posted Date: 2009-06-11

Last Posted Date: 2015-10-09

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 34

Registration Number: NCT00918658

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Spectroscopy of Breast Tissue

Completed

Conditions: Breast Cancer

First Posted Date: 2009-06-11

Last Posted Date: 2014-07-16

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 141

Registration Number: NCT00918216

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases

Phase 2

Terminated

Conditions: Metastatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Cognitive/Functional Effects

Interventions: Drug: sunitinib malate
Other: cognitive assessment

First Posted Date: 2009-05-29

Last Posted Date: 2014-09-29

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 14

Registration Number: NCT00910039

Locations: 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers

Terminated

Conditions: Breast Cancer
Fatigue
Long-term Effects Secondary to Cancer Therapy in Adults
Cognitive/Functional Effects

Interventions: Procedure: assessment of therapy complications
Procedure: cognitive assessment
Procedure: fatigue assessment and management

First Posted Date: 2009-05-28

Last Posted Date: 2015-10-02

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT00909662

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer

Withdrawn

Conditions: Kidney Cancer

First Posted Date: 2009-05-27

Last Posted Date: 2015-09-30

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT00908739

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy